Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6Myeloid 2Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Specimen Handling 80Fluorouracil 76Oxaliplatin 70Magnetic Resonance Spectroscopy 61Leucovorin 60Gemcitabine 56Bevacizumab 56Biopsy 41Capecitabine 40Irinotecan 38Cisplatin 37pembrolizumab 35Nivolumab 35Cetuximab 33durvalumab 30130-nm albumin-bound paclitaxel 29Paclitaxel 27atezolizumab 21Folfox protocol 20Radiotherapy 17Carboplatin 17Taxes 16dehydroftorafur 15Cyclophosphamide 15Radiation 14fludarabine 13X-Rays 13Surgical Procedures, Operative 13Albumin-Bound Paclitaxel 13trastuzumab deruxtecan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
olutasidenib × Gastrointestinal × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡